[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351636-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-351636-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","microrna-146a-protects-against-hepatocellular-carcinoma-through-suppression-of-ccl5","MicroRNA-146a Protects against Hepatocellular Carcinoma through Suppression of CCL5","","miR-146a regulates chronic inflammation and influences hepatocellular carcinoma (HCC) risk. Loss of miR-146a in a mouse HCC model caused a marked increase in tumor burden over 9 months, with the most pronounced phenotype in females. Mechanistically, miR-146a deficiency increased dysfunctional CD8+ T cells expressing high CCL5 and resembling age-associated T (Taa) cells, alongside elevated myeloid cells with an MDSC phenotype. Deleting Ccl5 restored tumor growth and aberrant myeloid populations to wild-type, yet did not normalize gross metabolic changes, indicating independent roles in HCC and metabolic disease.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/microrna-146a-protects-against-hepatocellular-carcinoma-through-suppression-of-ccl5/351636/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/microrna-146a-protects-against-hepatocellular-carcinoma-through-suppression-of-ccl5/351636.png","ImageObject",300,407,{"name":42,"@type":43},"Rizky","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What happens to tumor burden when miR-146a is lost in the HCC mouse model?","Question",{"text":63,"@type":64},"Loss of miR-146a leads to a significantly increased tumor burden over a 9-month timeframe in the mouse model of HCC.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the study connect miR-146a to immune populations and CCL5?",{"text":68,"@type":64},"miR-146a deficiency increases dysfunctional CD8+ T cells expressing high CCL5 (resembling Taa cells) and elevates myeloid cells with an MDSC phenotype, which suppress tumor immunity.",{"name":70,"@type":61,"acceptedAnswer":71},"What is the effect of deleting Ccl5 in miR-146a–deficient mice?",{"text":72,"@type":64},"Deleting Ccl5 from miR-146a–deficient mice returned tumor growth and the aberrant myeloid cell populations to wild-type levels, although it did not rescue the gross metabolic phenotype.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},351636,1790981441,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962085564807,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","RESEARCH ARTICLE  [https://doi.org/10.1158/2767-9764.CRC-25-0474](https://doi.org/10.1158/2767-9764.CRC-25-0474)  OPEN ACCESS  \nMicroRNA-146a Protects against Hepatocellular Carcinoma through Suppression of CCL5  \nMorgan C. Nelson1, Liam C. O’Malley1, Soh-Hyun Lee1†, Kaylyn M. Bauer1, Arevik Ghazaryan1, William W. Tang1, Chad VanSant-Webb2, Van B. Tran1, Colton Hernandez1, Ben Battistone1, Amber Thibeaux1, June L. Round1, Micah J. Drummond3, H. Atakan Ekiz1,4, Kimberley J. Evason2, Warren P. Voth1, and Ryan M. O’Connell1  \n􀀶  \nABSTRACT  \nThe miRNA microRNA-146a (miR-146a) regulates several aspects of chronic inflammation, including the hepatocellular carcinoma (HCC) risk factor, steatohepatitis. In this study, we find that the loss of miR-146a leads to a significantly increased tumor burden over a 9-month timeframe in a mouse model of HCC. Notably, this miR-146a􀀁/ 􀀁 phenotype is most pronounced in females, who are typically not sensitive to this model. Mechanistically, we identified increases in dysfunctional CD8+ T cells that express high levels of CCL5 and resemble age-associated T (Taa) cells, as well as elevated levels of myeloid cells with a myeloidderived suppressor cell (MDSC) phenotype, a class of myeloid cells that suppresses tumor immunity. Deletion of Ccl5 from miR-146a–deficient mice returned tumor growth and the aberrant myeloid cell populations to wild-type levels. Surprisingly, deletion of Ccl5 did not rescue the gross metabolic phenotype observed in miR-146a􀀁/ 􀀁 mice subjected to HCC  \ninduction, indicating that miR-146a plays an independent role in regulating HCC and metabolic disease. Taken together, this work reveals a critical host-protective role for miR-146a in HCC that is mechanistically dependent on CCL5 and wherein tumor burden correlates with two suppressive immune populations, providing an impetus for targeting these pathways to combat HCC. Furthermore, the correlations with tumor burden and Taa cells suggest that aging may increase HCC risk through the accumulation of CCL5-expressing Taa cells.  \nSignificance: The findings in this study highlight the potential of amiRNA-based therapy in the treatment of, and as a biomarker for, liver cancer, something especially promising given the liver’s avid uptake of RNA. Additionally, this work reveals possible causal roles in liver cancer for two unique immune cell types that are prevented by miR-146a.  \nIntroduction  \nLiver cancers account for more than 700,000 deaths worldwide each year ( 1), and hepatocellular carcinoma (HCC) is the most common form of primary liver cancer (2, 3) . Several liver conditions are thought to contribute to HCC risk, such as metabolic dysfunction-associated steatotic liver disease (MASLD), which is estimated to affect more than 30% of adults (4) . MASLD is the initial stage of an inflammatory process that may progress to metabolic dysfunction-associated steatohepatitis (MASH) and ultimately lead to  \n1Division of Microbiology and Immunology, Department of Pathology, University of Utah, Salt Lake City, Utah. 2Hunstman Cancer Institute, University of Utah, Salt Lake City, Utah. 3Department of Physical Therapy and Athletic Training, University of Utah, Salt Lake City, Utah. 4Department of Molecular Biology and Genetics, Izmir Institute of Technology, Urla, Turkey.  \nM.C. Nelson and L.C. O’Malley contributed equally to this article.  \n†Deceased.  \nCorresponding Author: Ryan M. O’Connell, Department of Pathology, University of Utah, 15 N Medical Drive East, Suite 1100, Salt Lake City, UT 84112. E-mail:  \n[ryan.oconnell@path.utah.edu](ryan.oconnell@path.utah.edu)  \ndoi: 10.1158/2767-9764.CRC-25-0474  \nThis open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.  \n©2026 The Authors; Published by the American Association for Cancer Research  \ncirrhosis (5) . About 80% of HCC cases present with cirrhosis (6), but the etiology of this disease progression is still unclear. Growing evi","cbCaiv0ErR0w8xOj","https://ap.wps.com/l/cbCaiv0ErR0w8xOj","pdf",41422089,15,"English","# Abstract\n# Significance\n# Introduction","[{\"question\":\"What happens to tumor burden when miR-146a is lost in the HCC mouse model?\",\"answer\":\"Loss of miR-146a leads to a significantly increased tumor burden over a 9-month timeframe in the mouse model of HCC.\"},{\"question\":\"How does the study connect miR-146a to immune populations and CCL5?\",\"answer\":\"miR-146a deficiency increases dysfunctional CD8+ T cells expressing high CCL5 (resembling Taa cells) and elevates myeloid cells with an MDSC phenotype, which suppress tumor immunity.\"},{\"question\":\"What is the effect of deleting Ccl5 in miR-146a–deficient mice?\",\"answer\":\"Deleting Ccl5 from miR-146a–deficient mice returned tumor growth and the aberrant myeloid cell populations to wild-type levels, although it did not rescue the gross metabolic phenotype.\"}]","MicroRNA-146a Protects against Hepatocellular Carcinoma through Suppression of CCL5 | PDF",1790095065,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/29038ffe4351d44f213b2cd4c0af157c.webp",983,1263,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1914bad748d858ecbab3729140b4a4b1.webp",982,1262,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/754f75a9ff46539e92db9b05b404035e.webp",981,1261,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4cb37af30c3cd22109ac3f71561f4adf.webp",980,1259]